Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies (Q38700484)

5 September 2017

title

Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies (English)

1 reference

5 September 2017

0 references

0 references

Jeffrey Cummings

1 reference

5 September 2017

Te-Jen Lai

1 reference

5 September 2017

Solaphat Hemrungrojn

1 reference

5 September 2017

E Mohandas

1 reference

5 September 2017

Sang Yun Kim

1 reference

5 September 2017

Girish Nair

1 reference

5 September 2017

Amitabh Dash

1 reference

5 September 2017

publication date

18 January 2016

1 reference

CNS Neuroscience & Therapeutics

5 September 2017

published in

1 reference

5 September 2017

1 reference

5 September 2017

1 reference

5 September 2017

page(s)

159-166

1 reference

An economic evaluation of donepezil in the treatment of Alzheimer's disease

5 September 2017

cites work

1 reference

Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials

21 January 2018

1 reference

Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex

21 January 2018

1 reference

Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease

21 January 2018

1 reference

Neurochemical basis for symptomatic treatment of Alzheimer's disease

21 January 2018

1 reference

The cholinergic deficiency syndrome and its therapeutic implications

21 January 2018

1 reference

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients

21 January 2018

1 reference

A description of agitation in a nursing home

21 January 2018

1 reference

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment

21 January 2018

1 reference

Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence

21 January 2018

1 reference

Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type

21 January 2018

1 reference

Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.

21 January 2018

1 reference

Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial

21 January 2018

1 reference

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

Safety and effectiveness of donepezil on behavioral symptoms in patients with Alzheimer disease.

21 January 2018

1 reference

Do atypical antipsychotics cause stroke?

21 January 2018

1 reference

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease

21 January 2018

1 reference

Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease.

21 January 2018

1 reference

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

21 January 2018

1 reference

Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders

21 January 2018

1 reference

Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease.

21 January 2018

1 reference

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

21 January 2018

1 reference

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

21 January 2018

1 reference

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

21 January 2018

1 reference

Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.

21 January 2018

1 reference

High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines

21 January 2018

1 reference

The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.

21 January 2018

1 reference

Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial

21 January 2018

1 reference

Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study

21 January 2018

1 reference

Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial

21 January 2018

1 reference

Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies

21 January 2018

1 reference

The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients

21 January 2018

1 reference

The incremental direct costs associated with behavioral symptoms in AD.

21 January 2018

1 reference

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation

21 January 2018

1 reference

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6203446

A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6203446

Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6203446

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6203446

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6203446

Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6203446

Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6203446

Behavioral symptoms in Alzheimer's disease: phenomenology and treatment.

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6203446

Managing behavioural and psychological symptoms in dementia

3 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26778658

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

1 reference

https://pubmed.ncbi.nlm.nih.gov/26778658

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long-term efficacy of donepezil for relapse of visual hallucinations in patients with dementia with Lewy bodies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26778658

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/CNS.12484

1 reference

5 September 2017

0 references

1 reference